Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.51

+2.7%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (6877)	8/12/2002 1:01:11 PM
From: Vector1	Read Replies (1) of 52153

Biomaven, it is interesting that existing public valuations are competing for VC money. I have long believed that BEXXAR was an approvable drug and would garner significant market share. However, one has to wonder why the FDA has given them such a hard time. Personality conflict, holes in the data, who knows. Sometimes life is just not fair. I expect they will get a full and fair hearing at the AC meeting. Given that the money is coming in as common stock it is clear to me that these vc funds think CRXA has a good shot. On the other hand I have been wrong and burned so many times on this stock I may be a contrary indicator. V1

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next